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Abstract
Background: The chemokine receptor CCR7 is a key organizer of the immune system. Gene targeting in mice
revealed that Ccr7-deficient animals are severely impaired in the induction of central and peripheral tolerance.
Due to these defects, Ccr7-deficient mice spontaneously develop multi-organ autoimmunity showing symptoms
similar to those observed in humans suffering from connective tissue autoimmune diseases. However, it is
unknown whether mutations of CCR7 are linked to autoimmunity in humans.
Results: DNA samples were collected from 160 patients suffering from connective tissue autoimmune disease
(Sjogren's syndrome, n = 40; systemic lupus erythematosus, SLE, n = 20 and systemic sclerosis, n = 100) and 40
health subjects (n = 40). All participants in this study were of German descent. Samples were screened for single
nucleotide polymorphisms (SNP) by sequencing the coding region of the CCR7 gene as well asthe exon flaking
intron sites and parts of the regions encoding for the 5'- and 3'-UTR. CCR7 variants were rare. We identified six
different sequence variants, which occurred in heterozygosis. The identified SNP were observed at position -60
C/T (observed 1x), +6,476 A/G (7x), +6,555 C/T (15x), +6,560 C/T (6x), +10,440 A/G (3x) and +11,475 C/A (1x).
Four of these variants (+6,476 A/G, +6,555 C/T, +6,560 C/T and +10,440 A/G) display allelic frequencies between
1% and 5 % and were present in both patients and control groups. The variants +6,476 A/G, +6,555 C/T, +6,560
C/T are located in the intron 2, while the +10,440 A/G variant corresponds to a silent mutation in exon 3. The
variants -60 C/T and +11,475 C/A which are located at the 5'-UTR and 3-UTR respectively, display allelic
frequencies below 1%. No correlation between these variants and the autoimmune diseases investigated could be
observed. However, reporter gene expression assay demonstrated that the mutation at the -60 C/T position in
homozygosis leads to reduced luciferase activity.
Conclusion: These results suggest that variants of CCR7 gene occur at an extremely low frequency in the
German population and that neither Sjogren's syndrome, systemic lupus erythematosus, nor systemic sclerosis
are associated with these variants. Nevertheless, the decreased luciferase activity observed in cells transfected
with the promoter region bearing the -60 C/T mutation suggests that this CCR7 variant could potentially lead to
increased susceptibility to autoimmunity.
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Background
The functional organization of the immune system relies
on the orchestrated migration of its cellular components.
Along with adhesion molecules, chemokines and their
receptors play an essential role in directing the complex
network of continuous cell trafficking, homing to lym-
phoid and non-lymphoid organs and egressing from these
sites [1]. The CC-chemokine receptor 7 (CCR7) and its lig-
ands, CCL19 and CCL21, have been identified as one of
the key players in lymphocyte and dendritic cell migration
[2,3]. Ccr7 is required for the homing of naïve T cells via
high endothelial venules (HEV) to lymph nodes and
Peyer's patches, the correct positioning of B cells and T
cells within secondary lymphoid organs, as well as the
egress of dendritic cells from the skin to the draining
lymph nodes under both steady state and inflammatory
conditions [2,4]. Furthermore, together with Cxcr5, Ccr7
is required for the development of lymph nodes and
Peyer's patch by guiding lymphoid tissue inducing cells to
lymph node anlagen [5]. Consequently, gene-targeted
mice deficient in Ccr7 show profound alterations of the
immune system that result in delayed and impaired
immune responses [2,4].
We have recently demonstrated that ccr7-deficient mice
show gross alterations in thymus architecture with loss of
the classical cortex-medulla segregation [6]. This defect
seems to be due to impaired migration of early T cell pro-
genitors from the cortico-medullary junction towards the
subcapsular regions. Others have suggested that positively
selected thymocytes need ccr7 to migrate from the cortex
into the medulla [7]. These migration defects result in
breakdown of central tolerance. Consequently, Ccr7-defi-
cient mice show prominent cellular infiltrates in several
organs including salivary and lachrymal glands, stomach,
pancreas and liver [7,8]. In addition, Ccr7-/- mice display
increased titers of circulating auto-antibodies to nuclear
and non-nuclear tissue-antigens as well as IgG deposits on
renal glomeruli. Ccr7-deficient mice show increased sus-
ceptibility to streptozotocin-induced diabetes as well as
manifestations of ongoing spontaneous autoimmune
renal disease [8]. Since Ccr7 deficiency in mice results in
morphological and functional alterations, which are also
characteristic for various human autoimmune diseases,
we sequenced part of the CCR7 locus in 160 autoimmune
patients and 40 healthy controls.
Results
Analysis of the CCR7 sequences
We recently demonstrated that Ccr7-deficient mice are
prone to develop generalized multi-organ autoimmunity
and spontaneously display symptoms of human connec-
tive tissue autoimmune diseases [8]. To investigate a pos-
sible correlation between CCR7 variants and susceptibility
to the development of autoimmune diseases in humans,
we performed a sequencing analysis of the CCR7 gene in
100 patients suffering from systemic sclerosis, in 40
patients with Sjogren's syndrome and in 20 patients suf-
fering from SLE. Disease classification criteria of the inves-
tigated patients are shown in Table 1. Age-matched
healthy individuals served as controls. Both patients and
controls were of German descent. We investigated CCR7
variants by direct sequencing of its coding sequence, flak-
ing introns sites (accounting for splice variants) and the
core promoter, encompassing in toto 3 kb. This approach
allows the identification of mutations in the coding
sequence as well as in regulatory elements which could
influence CCR7 expression.
We identified six different sequence variants which
occurred heterozygously. Since the transcriptional starting
point of the CCR7 gene has not yet been mapped, the
location of the variants is given relative to the position of
the first base coding for the methionine of exon 1 which
was set to position +1 and the preceding base to -1. Six
SNP were identified at positions -60 C/T (observed 1x),
+6,476 A/G (7x), +6,555 C/T (15x), +6,560 C/T (6x),
+10,440 A/G (3x) and +11,475 C/A (1x; see Table 2 and
Fig. 1). All genotype frequencies were consistent with
Hardy-Weinberg distribution for all variants analyzed and
in all patient and control cohorts (p < 0.05).
Four out of six identified SNP (-60 C/T, +6,476 A/G,
+6,555 C/T and +11,475 C/A) have not been described so
far. The variants +6,560 C/T and +10,440 A/G were previ-
ously described in the HapMap SNP database and corre-
spond to the rs3136689 and rs2229095 SNP, respectively
(Table 2). Only two of the observed variants (+6,476 A/G
and +10,440 A/G) were located within the CCR7 coding
sequence (Table 2 and Fig. 1). The +6,476 A/G variant at
exon 2 resulted in an exchange at the 1st base of the ATG-
codon which in turn resulted in a methionine to valine
exchange. This mutation did not correlated with increased
susceptibility to the diseases investigated here since simi-
lar frequencies were observed in patients and controls
(Table 2). The +10,440 A/G variant (rs2229095, Hap-
Map) of exon 3 was not observed in the control group
(Table 2). However, as this mutation resulted in a silent
transversion at the 3rd base of codon CAA, this variant is
also likely to be irrelevant for susceptibility to connective
tissue autoimmune diseases. In addition, the frequency of
the allele G observed in the patient group (1% in patients
suffering from systemic sclerosis and 1.25% in patients
suffering from Sjogren's syndrome (Table 2), was similar
to the allelic frequency (0.8%) previously observed in
Utah residents with ancestry from northern and western
Europe (CEU HapMap samples, n = 60). The mutations
+6,555 C/T and +6,560 C/T (rs3136689; HapMap) were
located in intron 2. The +6,555 C/T SNP was observed in
all patients and control groups at similar frequenciesBMC Genetics 2007, 8:33 http://www.biomedcentral.com/1471-2156/8/33
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(Table 2). In contrast, the rs3136689 SNP was only
observed in patients suffering from systemic sclerosis and
in the control individuals. The allelic frequency of this
SNP was similar in both groups (2.0% and 2.5%, respec-
tively; Table 2). Interestingly, the frequency of the allele T
observed in the CEU population differs from that
observed in our control samples (0.8% vs. 2.5%, respec-
tively, Table 2). It is however of note that our control
group consists of healthy German subjects without signs
of autoimmune diseases and tested negative for the above
mentioned diseases. Therefore, it seems likely that the dis-
crepancies observed between the CEU population and our
control group are a consequence of the small size of the
compared samples (n = 60 and n = 40, respectively). The
variants -60 C/T and +11,475 C/A were located in the 5'-
UTR and 3'-UTR respectively. Both mutations occurred at
a very low allelic frequency (0.5%) and were only detected
in the group of patients suffering from systemic sclerosis
(Table 2). The absence of these rare variants in the other
groups likely reflects the small size of the samples rather
than a correlation between these alleles and susceptibility
to systemic sclerosis. Nevertheless, mutations in such reg-
ulatory regions of the gene could lead to decreased CCR7-
expression and therefore increases the susceptibility of
individual subjects to develop autoimmune disease.
In summary, CCR7 variants were rare among patients and
controls with allelic frequencies always ≤ 5%. In addition,
no clear correlation has been found between autoimmu-
nity and the observed CCR7 variants. Furthermore, the
results largely exclude the possibility that rare sequence
variants within the coding sequences, flanking intron sites
and the CCR7 core promoter accumulate in subjects suf-
fering from autoimmune diseases investigated in this
study.
The -60 C/T mutation leads to reduced reporter gene 
expression in vitro
Since the exchange at position -60 might affect the CCR7
promoter activity, we further characterized this variant. In
silico analysis revealed a putative binding site for AP-2/
Ikaros at position -77 to -47. To functionally test whether
this variant has any effect on CCR7 expression, we cloned
a 563 bp fragment of the wild type and the variant pro-
moter into a firefly luciferase reporter plasmid. To adjust
for transfection efficiency, each construct was co-trans-
fected with a renilla luciferase reporter plasmid. Promoter
activity has been tested by transfecting the T cell line
HUT78 using a conventional electroporation protocol. As
shown in Fig. 2A the relative luciferase activity of HUT78
cells transfected with the construct bearing the mutant
promoter was roughly decreased twofold in comparison
to that of cells transfected with the construct bearing the
wild type promoter. This result indicates that the -60 C/T
mutation leads to a reduction of the CCR7 promoter activ-
ity. However, we can not currently rule out the possibility
Table 1: Disease classification criteria
Disease Criteria % of patients fulfilling the criteria
SLE Malar rash 90
Discoid rash 55
Photosensitivity 70
Oral ulcerations 40
Non-erosive arthritis 90
Serositis 35
Glomerulonephritis 40
Neurological involvement 15
Hematological involvement 65
Immunological involvement 75
Antinuclear antibodies 100
Sjogren's syndrome Ocular symptoms 95
Oral symptoms 87,5
Objective involvement of lacrimal glands 92,5
Pathological salivary gland biopsy 32,5
Objective involvement of salivary glands 75
Presence of autoantibodies against Ro/La 90
systemic sclerosis Proximal scleroderma 100
Sclerodactyly 44
Acral ulcerations 36
Bilateral pulmonary fibrosis 18
Patients analyzed in the present study have been classified based on the listed criteria.BMC Genetics 2007, 8:33 http://www.biomedcentral.com/1471-2156/8/33
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that this mutation has translational effects secondary to
mRNA structural differences or mRNA stability. In order
to compare the function of the wild type and mutant pro-
moters in a more appropriated system taking into account
the variability found normally in human populations, we
transfected primary T-cells isolated from the peripheral
blood of 13 unrelated healthy donors using Amaxa trans-
fection technology. Under these experimental conditions
we found that in 2 of the 13 donors the -60 C/T exchange
also significantly reduced the CCR7  promoter activity
(Fig. 2B) while no difference could be detected in the 11
remaining donors (data not shown). From the two donors
that showed reduced promoter activity, blood was recol-
lected 2 to 4 weeks later and the transfection experiment
was repeated giving similar results (Fig. 2B). Since the
results obtained by the transfection of primary cells are
likely to reflect the situation observed in human popula-
tions more reliably than those obtained by the transfec-
tion of the HUT78 cell line, our data indicate that subject-
specific mechanisms might influence the expression of
CCR7 in T cells. Therefore, the -60 C/T mutation in com-
bination with yet unknown genetic or environmental fac-
Schematic overview of the CCR7 gene located at chromosome 17q12 – q21.2 Figure 1
Schematic overview of the CCR7 gene located at chromosome 17q12 – q21.2. The enlarged areas represent the three exons 
with their flanking regions that have been subjected to sequence analysis. The positions of the observed SNP are given in rela-
tion to the first base of exon 1 which has been set to +1.
Table 2: Location and frequency of the observed SNP
Position Location SNP Exchange in 
amino acid?
Population Number of subjects 
carrying the SNP
Number of analyzed 
subjects
Allelic 
frequency (%)
Reference
-60 5'-UTR C/T Systemic sclerosis 1 100 0.50 this work
SLE 0 20 0.00
Sjogren's syndrome 0 40 0.00
Controls 0 40 0.00
+6,476 exon 2 A/G methionine to 
valine
Systemic sclerosis 4 100 2.00 this work
SLE 0 20 0.00
Sjogren's syndrome 1 40 1.25
Controls 2 40 2.50
+6,555 intron 2 C/T Systemic sclerosis 6 100 3.00 this work
SLE 2 20 5.00
Sjogren's syndrome 3 40 3.75
Controls 4 40 5.00
+6,560 intron 2 C/T Systemic sclerosis 4 100 2.00 rs3136689
SLE 0 20 0.00 (HapMap)
Sjogren's syndrome 0 40 0.00
Controls 2 40 2.50
+10,440 exon 3 A/G no exchange Systemic sclerosis 2 100 1.00 rs2229095
SLE 0 20 0.00 (HapMap)
Sjogren's syndrome 1 40 1.25
Controls 0 40 0.00
+11,475 3'-UTR C/A Systemic sclerosis 1 100 0.50 this work
SLE 0 20 0.00
Sjogren's syndrome 0 40 0.00
Controls 0 40 0.00
Positions of the observed SNP are given relative to the first base coding for the Methionine of exon 1 which has been set to position +1 and the preceding base to -1. SNP, 
single nucleotide polymorphism. The most frequent allele is named first.BMC Genetics 2007, 8:33 http://www.biomedcentral.com/1471-2156/8/33
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tors could potentially increase the susceptibility of
individual persons to develop autoimmunity.
Discussion
CCR7 is known as a key regulator of the immune system.
Initial studies demonstrated that this receptor is required
for the homing of naïve T cells into lymph node and
Peyer's patches [2]. More recently we showed that den-
dritic cells in lung and intestine require Ccr7 to actively
transport inhaled and ingested antigen into the draining
lymph nodes of these organs in order to induce peripheral
tolerance towards innocuous antigen [9,10]. Further-
more, Ccr7 expression is required for maintenance of the
thymic architecture and appropriate negative selection
(ref. [6] and unpublished data ACD-M and RF). Due to
these defects, Ccr7-deficient mice are severely impaired in
maintaining both peripheral and central tolerance [8-10].
Based on data derived from Ccr7-deficient mice we tested
the hypothesis that mutations in the CCR7 gene might be
associated with the development of autoimmune diseases
in humans. However, data derived from 160 patients suf-
fering from connective tissue autoimmune diseases and
40 healthy individuals revealed that genomic variants in
the analyzed regions of the CCR7 gene locus occur at a
very low frequency in the German population. In addi-
tion, the allelic frequencies of the identified variants were
very low in all of the cohorts analyzed. These data demon-
strate that mutations in the CCR7 gene do not positively
correlate with development of the investigated autoim-
mune diseases. Interestingly, one of the identified muta-
tions was located into the promoter region of the CCR7
gene. The activity of the mutant promoter was assessed by
transient transfection of constructs bearing the luciferase
gene into either HUT78 T cells or into primary T-cells.
Luciferase expression driven by the mutant promoter was
reduced in HUT78 cells to approximately 50% in compar-
ison to that driven by the wild type promoter. Similar
results were observed for primary T cells of 2 out of 13
donors analyzed. These data suggest that yet unknown
factors can modulate the expression of CCR7 varying from
one subject to another. This leaves the possibility open
that rare mutations occurring in regulatory regions of the
CCR7 gene could result in increased susceptibility to the
development of autoimmune diseases in individual sub-
jects.
Methods
Patients
Blood samples of patients with connective tissue diseases
were collected in a study on genetic risk factors of autoim-
mune diseases approved by the local ethical committee.
All patients were visiting the outpatient clinics of the
Department of Clinical Immunology of Hannover Medi-
cal School, Germany. The patients with the connective tis-
sue diseases SLE (n = 20, 85 % female), systemic sclerosis
(n = 100, 80 % female) and primary Sjogren's syndrome
(n = 40, 90 % female) were all German Caucasians from
the area of Hannover and were classified according to the
respective classification criteria [11-13]. Disease classifica-
tion criteria of the analyzed patients are shown in Table 1.
None of the patients with Sjögren's syndrome fulfilled the
criteria of SLE or systemic sclerosis. Since in the absence of
complaints of dry eyes or mouth a salivary gland biopsy
was not performed, it cannot be ruled out that some of the
patients with SLE or systemic sclerosis may have suffered
from secondary Sjogren's syndrome. In addition, 40 iso-
lates of healthy German Caucasian subjects without signs
of the above-mentioned autoimmune diseases served as
control. The average age of the patients was 45.9 +- 13.0
Relative luciferase activity of the wild type promoter (WT)  and a promoter construct bearing the -60 C/T mutation in  homozygosis Figure 2
Relative luciferase activity of the wild type promoter (WT) 
and a promoter construct bearing the -60 C/T mutation in 
homozygosis. (A): relative luciferase activity in HUT78 cells 
following transfection of the promoter constructs by electro-
poration. Data shown is representative of three independent 
experiments. (B): relative luciferase activity in primary T-cells 
that were transfected with the promoter constructs using 
Amaxa transfection technology. Two independent experi-
ments (exp.) were performed. In each experiment primary 
T-cells from 13 donors were used. Shown are results from 
donor #2 and donor #9. No differences between WT and 
mutant promoter activity were observed in the remaining 11 
donors. Error bars represent the SEM of triplicates. Statistic 
analysis was performed applying unpaired t-test. Values < 
0.05 were considered significant (* = p < 0.05, ** = p < 0.01).BMC Genetics 2007, 8:33 http://www.biomedcentral.com/1471-2156/8/33
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years and of controls 42.8 +- 12.1 years (mean +/- SD).
Following informed written consent, blood samples were
collected from each individual and genomic DNA was
extracted from blood using standard procedures.
DNA isolation and PCR
Genomic DNA was prepared from peripheral blood cells
using the QIAamp DNA Blood Mini Kit (Qiagen). The cod-
ing regions as well as flanking regions of all three exons of
the  CCR7  gene were amplified using the primer pairs
shown in Table 3. The PCR reactions were performed in
50  μl buffer (buffer Y, peqLab) containing 100 ng of
human genomic DNA, 50 picomol of each primer, 2.5
nmol of each deoxyribonucleoside triphosphate, and 1.5
units of Taq polymerase. PCR reactions were performed
for 40 cycles consisting of 8 seconds at 94°C, 30 seconds
at 60°C and 90 seconds at 72°C following an initial dena-
turation step of 4 minutes at 95°C. For sequencing, PCR
products were purified using Microcon YM-100 tubes
(Milian, Italy). In some experiments PCR products were
purified using the QIAquick gel extraction kit, (QIAgen).
Sequencing
DNA sequencing was carried out using an ABI Prism
3100-Avant genetic analyser (Applied Biosystems) and
ABI PRISM BigDye Terminator v1.1 Cycle Sequencing Kit
according to the manufactures instructions. Sequence
PCR reactions were done for 25 cycles with an annealing
temperature of 50°C. The average length of primary
sequence was approximately 480 bp. The sequence of the
2.272 bp PCR product spanning exon 3 was revealed
applying five internal primers that allowed for an overlap
of at least 30 bp between the individual reactions. All pol-
ymorphisms detected were confirmed by sequencing of
the complementary strand (primer not shown). Primers
used are listed in Table 3.
Cloning of the CCR7 promoter constructs and luciferase 
assays
In order to test whether -60 C/T variant has any functional
consequences on CCR7 expression we cloned a putative
563 bp promoter fragment upstream from exon 1. Con-
structs were amplified from genomic DNA using the
Expand High Fidelity PCR System (Roche). For amplifica-
tion of the mutant promoter bearing the C/T exchange in
position -60, genomic DNA of the patient carrying this
SNP was used as template (see Table 2 and Fig. 1). The
primers used for the amplification (5'-CTC GAG ATC TGA
AGG GGG GAG AAA AAA GAT ACA TCG TG-3' and 5'-
TGC CAA GCT TGA CGC TCT CTG GGC GGT AAA ACC-
3') include 10 additional bases containing cleavage sites
for the endonucleases BglII and HindIII respectively. The
PCR reaction was performed under standard conditions
for 40 cycles with an annealing temperature of 58°C. Sub-
sequent to purification of PCR products via gel extraction
(QIAquick gel extraction kit, QIAgen), products were
digested for 1 h with HindIII/BglII at 50°C and cloned
into the multiple cloning site of a firefly luciferase reporter
plasmid (pGL2-basic, Promega). All inserts were checked
for correct orientation and sequence.
The functionality of the cloned promoters has been tested
by measuring luciferase activity in HUT78 cells and pri-
mary T cells transiently transfected with the constructs
bearing either the wild type or the mutant promoter. To
adjust for transfection efficiency, each construct was co-
transfected with a renilla luciferase reporter plasmid.
Transfection of HUT78 cells has been performed using a
conventional eletroporation protocol. For the transfection
of primary T cells, lymphocytes were isolated from 20 ml
freshly collected venous blood applying ficoll gradient
centrifugation. After washing twice in PBS, lymphocytes
were stained with a biotinylated mouse-anti-human
Table 3: Primer used
Primer Sequence Primer application
CCR7_1F GAT CCT ATG ACC AGC GAC TGT C Forward amplification primer exon 1
Sequencing primer exon 1
CCR7_1R AGT AGC TTC CAA TGC CCA CCA AA Reverse amplification primer exon 1
CCR7_2F TAC CCC ACG ACC TCA TAG C Forward amplification primer exon 2
CCR7_2R GTT GGA CTC CCC TAG CCC TAC TC Reverse amplification primer exon 2
CCR7_3F GAT GAT GCG GAC CTC ACG ATG Forward amplification primer exon 3
CCR7_3R CAT GAG GAG AGG TTT TCA GTC CC Reverse amplification primer exon 3
SeqCCR7_2F ACA AGA AGG AGG TGA GGA CAG TGA Sequencing primer exon 2
SeqCCR7_3F_1 GTT GGA GCC ACC CAG CTA AAC TG Sequencing primer exon 3
SeqCCR7_3F_2 GGG TCT TCG GTG TCC ACT TTT GC Sequencing primer exon 3
SeqCCR7_3F_3 TGC TCC AGG CAC GCA ACT TTG A Sequencing primer exon 3
SeqCCR7_3F_4 GCA GAT GCA ATG ACT CAG GAC Sequencing primer exon 3
SeqCCR7_3F_5 CAG CTG GTC AA ACA AAC TCT C Sequencing primer exon 3
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CD20 (Caltag) monoclonal antibody followed by strepta-
vidin coated magnetic particles (Miltenyi Biotec, Ger-
many). CD20+  cells were depleted from the cell
suspension using the autoMACS cell sorter system
(Miltenyi). CD20-negative, non-adherent cells, which
were > 85% T cells, were co-transfected with the firefly
luciferase reporter plasmid including the promoter con-
struct and a renilla luciferase reporter plasmid (pRL-TK)
applying the Human T Cell Nucleofector Kit and the
Nucleofector device (AMAXA). In addition, other T cell
fractions were co-transfected with the pGL2-basic vector
(without any promoter construct) and pRL-TK. For each
donor electroporation was done in triplicate. Following
electroporation, cells were cultured for at least 24 hrs at
37°C, 5% CO2. Luciferase activity in lysates of the trans-
fected cells was determined in a luminometer (Lumat LB
9507, Berthold) using the Dual-Luciferase Reporter Assay
System (Promega) according to the manufacture's guide-
lines. Relative luciferase activity (RLA) was calculated as
follows:
Statistical analysis
Allelic frequencies were ascertained by direct counting
and subsequently analyzed according to the χ2 method.
Deviations from Hardy-Weinberg equilibrium were calcu-
lated with p-values < 0.05 being considered as significant.
Statistical analysis of the promoter activity assay was done
using unpaired t-test with p-values < 0.05 being consid-
ered significant (GraphPad Prism 4.03; GraphPad Soft-
ware, San Diego, CA).
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firefly luciferase activity of pl
÷
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